Shandong Xinlu Pharmaceutical Co., Ltd.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of apalutamide tablets (specification: 60 mg) owned by Shandong Xinlu Pharmaceutical Technology Co., Ltd. and produced by Shanghai Chuangnuo Pharmaceutical Co., Ltd. and apalutamide tablets (trade name: Erleada®/Ansenke®, specification: 60 mg) licensed by Janssen-Cilag International NV in healthy Chinese male subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test and reference preparations of apalutamide tablets taken orally in healthy Chinese male subjects.

Primary objective: To evaluate the bioequivalence of the two preparations in Chinese healthy subjects in the fasting and postprandial states, using the reference preparation of Aguratimod tablets (trade name: Edexin, specification: 25 mg) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation and the test preparation of Aguratimod tablets (specification: 25 mg) developed by Shandong Xinlu Pharmaceutical Technology Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.